Preliminary results of a phase 1A/1B study of BGB-A317, an anti-PD1 monoclonal antibody (mAb), in patients with advanced hepatocellular carcinoma (HCC)

被引：0

作者：

Yen Chia-Jui ^{[1
]}

Benjamin, Markman ^{[2
]}

Chao Yee ^{[3
]}

Andrew, Hill ^{[4
]}

Kang Jinyu ^{[5
]}

Wang Lai ^{[5
]}

Li Kang ^{[5
]}

Qi Qinzhou ^{[5
]}

Wu Zhong ^{[6
]}

Gan Hui ^{[7
]}

机构：

[1] Natl Cheng Kung Univ Hosp, Tainan, Taiwan

[2] Monash Med Ctr, Clayton, Vic, Australia

[3] Taipei Vet Gen Hosp, Taipei, Taiwan

[4] Tasman Oncol Res Ltd, Southport, Qld, Australia

[5] BeiGene Beijing Co Ltd, Beijing, Peoples R China

[6] BeiGene USA Inc, Ft Lee, NJ USA

[7] Austin Hosp, Melbourne, Vic, Australia

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P - 140

引用

页数：1